Search:

Home Index Help Contact

 

Here is a convenient index of articles that have appeared in recent issues of the journal. The article titles are presented, with the keyword given first. Click on any title to find out more about the content.

 

Article title

Issue

 

Acute myeloid leukaemia: Update on novel drugs for use in acute myeloid leukaemia
Jonathan Kell MB MD MRCPath Consultant Haematologist, University Hospital of Wales, Cardiff
1.1
Acute promyelocytic leukaemia: The diagnosis and management of APL
David Grimwade PhD MRCP FRCPath Professor of Molecular Haematology, Department of Medical and Molecular Genetics, King’s College London School of Medicine
3.2
  • View references
Antithrombotic agents in myeloproliferative disorders
Raffaele Landolfi MD Professor of Internal Medicine, Catholic University, Rome; Tiziano Barbui MD Professor of Haematology, Ospedali Riuniti, Bergamo, Italy
1.3

 

Biphenotypic leukaemia: The current status of biphenotypic leukaemia
Ronan Swords MB MRCPI FRCPath Specialist Registrar in Haematology, University College Hospital, Galway, Ireland; Yesid Alvarado MD Fellow in Hematology/Oncology,
2.2
Bone marrow pathology: The importance of bone marrow pathology in CMPDs
Bridget S Wilkins FRCPath MB BChir Senior Lecturer in Haematopathology, Department of Histopathology, Royal Victoria Hospital, Newcastle-upon-Tyne
1.3
Budd–Chiari syndrome – a delayed diagnosis
Nauman M Butt MBChB MRCP FRCPath MD Consultant Haematologist, Department of Haematology, Arrowe Park Hospital, Upton, Wirral
2.2

 

Case study: Response to peginterferon alfa – one patient’s experience
Catherine J Rea MA MRCP Specialist Registrar in Haematology, Guy’s and St Thomas’ NHS Foundation Trust, London
3.2
Childhood: Chronic myeloproliferative disorders in childhood
Georgina W Hall MBBS BSc PhD FRCP FRCPath FRCPCH Consultant Paediatric Haematologist, John Radcliffe Hospital, Oxford
2.2
Chronic myeloid leukaemia: Is chronic myeloid leukaemia curable with drugs?
Mhairi Copland BSc(Hons) MB ChB PhD MRCP FRCPath Clinical Senior Lecturer and Honorary Consultant in Haematology, Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Gartnavel General Hospital, Glasgow
3.2
  • View references
CMML: How to treat chronic myelomonocytic leukaemia
Mark Drummond PhD FRCPath Consultant Haematologist and Honorary Senior Clinical Lecturer, Haematology Laboratories, Gartnavel General Hospital, Glasgow
3.1
Comment: At last, the malady of mystery makes a name for itself
John Reilly, Editor
1.2
Comment: Can one pill a day really keep cancer at bay?
John Reilly, Editor
1.3
Comment: Chronic myeloproliferative disorders take centre stage
John Reilly, Editor
2.2
Comment: Clinical trials in CMPDs – the stage is set
John Reilly, Editor
2.1
Comment: JAK2 and myeloproliferative neoplasms – an evolving story
John Reilly, Editor
3.2
Comment: MPNs and clinical trials – from famine to feast?
John Reilly, Editor
3.1
Comment: On myeloid disorders – and publishing the unthinkable
John Reilly, Editor
1.1
Comment: The classification of MPNs: WHO and why?
John Reilly, Editor
2.3
Compliance: How pretreatment advice can help keep patients on therapy
Heather Rawle BA MSc DClinPsych PGDip Clinical Health Psychologist; Yvonne Francis BSc DipHE Clinical Nurse Specialist; Claire N Harrison DM FRCP FRCPath Consultant Haematologist; Ann Marie Jahn-Fermor MPD patient, Guy’s and St Thomas’ NHS Foundation Trust, London
2.3

 

Dasatinib: a new therapy for myeloproliferative disorders
Richard E Clark MA MD FRCP FRCPath Professor of Haematology/Consultant Haematologist, University Department of Haematology, Royal Liverpool University Hospital
1.3
Demethylation agents – do they have a future?
Deborah Moulton MBChB MRCP Specialist Registrar in Haematology; Kavita Raj MRCP FRCPath Consultant Haematologist, Department of Haematology, Guy’s Hospital, London
2.3
  • View references

 

Economics: How will we afford new cancer drugs?
Steve Williamson MSc Onc MRPharmS Consultant Pharmacist in Cancer Services, Northumbria Healthcare NHS Foundation Trust
2.2
Eosinophilic syndromes: The diagnosis and treatment of eosinophilic syndromes
Lisa M Baumann Kreuziger MD Fellow; David P Steensma MD FACP Associate Professor of Medicine; Associate Professor of Oncology, Mayo Clinic, Rochester, Minnesota
1.2
Essential thrombocythaemia: ET – a difficult case
John Reilly BSc MD FRCP FRCPath Consultant Haematologist and Professor of Haematology, University Division of Genomic Medicine, Royal Hallamshire Hospital, Sheffield
2.1
Essential thrombocythaemia: EXELS: a new long-term observational study in ET
Claire N Harrison DM FRCP MRCPath Consultant Haematologist, Department of Haematology, St Thomas’ Hospital, London
1.3
Essential thrombocythaemia: How to manage palpitations when treating ET
Manuel Martínez-Sellés MD PhD Cardiology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
3.2
Essential thrombocythaemia: treatment for young patients
Susan E Robinson MB BS MSc MRCP DipRCPath Specialist Registrar; Claire N Harrison DM FRCP MRCPath Consultant Haematologist, St Thomas’ Hospital, London
1.1

 

Innovation Awards 2009
2.3

 

JAK2 inhibitors: Using JAK2 inhibitors in myeloproliferative neoplasms
Laurent Knoops MD PhD Postdoctoral Researcher, Université catholique de Louvain, Brussels, Belgium; Carmen C Diaconu PhD Senior Scientist, Stefan S Nicolau Institute of Virology, Bucharest, Romania; Stefan N Constantinescu MD PhD Professor, Université catholique de Louvain and Ludwig Institute for Cancer Research, Brussels, Belgium
2.1
JMML: Juvenile myelomonocytic leukaemia – an update
Anupama G Rao MRCPCH MRCPath Specialist Registrar; Phil J Ancliff MRCP MRCPath Consultant Haematologist, Great Ormond Street Hospital, London
2.3
  • View references

 

Lenalidomide for MDS with deletion of 5q
Jonathan Kell MB MD FRCPath Consultant Haematologist, University Hospital of Wales, Cardiff
2.2

 

Molecular defects: Identifying molecular defects in myeloproliferative disease
Paresh Vyas FRCP FRCPath DPhil Consultant Haematologist and Reader in Haemato-Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford
1.1
Molecular diagnosis of chronic MPNs
Anna L Pozo MA BMBCh MRCP Specialist Registrar in Haematology; Anthony J Bench MA PhD Senior Scientist; Wendy N Erber MD DPhil FRCPA Consultant Haematologist, Department of Haematology, Addenbrooke’s Hospital, Cambridge
3.1
Myelodysplasia: Transfusional support and iron chelation in myelodysplasia
Sally Killick MD MRCPath FRCP Consultant Haematologist, The Royal Bournemouth and Christchurch NHS Foundation Trust, Bournemouth
1.2
Myelofibrosis: Splenectomy in myelofibrosis: indications and risks
John Reilly BSc MD FRCP FRCPath Consultant Haematologist and Professor of Haematology, University Division of Genomic Medicine, Royal Hallamshire Hospital, Sheffield
1.1

 

Nilotinib: a second-generation BCR-ABL kinase inhibitor
Mhairi Copland BSc MB ChB PhD MRCP MRCPath Clinical Senior Lecturer and Honorary Consultant in Haematology, University of Glasgow and Glasgow Royal Infirmary
2.1
Nurse-led clinic: A nurse/pharmacist-led service for managing patients with MPNs at a distance
Theresa Peters RGN BSc Clinical Nurse Specialist; Sue Coppin RGN (Dip) Junior Sister, Oncology/Haematology Outpatients; Vicki Clarke BPharm (Hons) MRPharmS DipClinPharm Pharmacist Independent Prescriber; Sarah A Wexler MBBS MRCP FRCPath Consultant Haematologist; Christopher JC Knechtli MBChB PhD FRCP FRCPath Consultant Haematologist, Haematology Service, Royal United Hospital Bath
3.1
Nurse-led clinic: The role of the nurse-led clinic in the long-term care of patients with MPDs
Michelle Taylor RGN Haematology Nurse Practitioner; E Sarah Green MA FRCP FRCPath Consultant Haematologist, The Great Western Hospital, Swindon
2.1

 

Paroxysmal nocturnal haemoglobinuria: An update on the diagnosis and management of PNH
Richard Kelly MD Research Fellow, Department of Haematology; Stephen Richards PhD Consultant Clinical Scientist, Haematology Malignancy Diagnostic Service; Peter Hillmen MRCP FRCP PhD FRCPath Consultant Haematologist, Department of Haematology, St James’ University Hospital, Leeds
2.3
Polycythaemia vera: Simplifying PV diagnosis in the light of the JAK2 mutation
Mary Frances McMullin MD FRCPath FRCPEdin Professor, Queen’s University, Belfast; Consultant Haematologist, Belfast City Hospital
1.2
Primary myelofibrosis: Current treatment options in primary myelofibrosis
Giovanni Barosi MD Clinical Epidemiology Unit and Centre for the Study of Myelofibrosis, IRCCS Policlinico S Matteo Foundation, Pavia, Italy
1.3
Primary myelofibrosis: Stem cell transplantation in primary myelofibrosis
Damiano Rondelli MD Associate Professor of Medicine, University of Illinois at Chicago; Ronald Hoffman MD Professor of Medicine, Director of Myeloproliferative Disorders Program, Mount Sinai School of Medicine, New York, NY
1.2

 

Stem cell transplantation: Allogeneic SCT in AML: who should you transplant?
Charles Craddock BMBCh FRCPath DPhil Consultant Haematologist, Centre for Clinical Haematology, University Hospital, Birmingham
3.1
Stem cell transplantation: Allogeneic SCT in chronic phase CML: who should you transplant?
Jiri Pavlu MD MRCP FRCPath Bone Marrow Transplant Co-ordinator; Jane F Apperley MD FRCP FRCPath Professor of Haemato-Oncology, Imperial College and Imperial College Healthcare NHS Trust, London
3.2
  • View references
Systemic mastocytosis: The diagnosis and treatment of systemic mastocytosis
Alfonso Quintás-Cardama MD Fellow; Srdan Verstovsek MD PhD Associate Professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2.1

 


The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.
Copyright (©) 2010 Hayward Group Ltd. The title Myeloproliferative Disorders in practice is the property of Hayward Group Ltd and, together with the content, is bound by copyright. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk